All Oncology News

Intraperitoneal and intravenous paclitaxel plus S-1 improved OS over intravenous paclitaxel and S-1 alone in gastric cancer with peritoneal metastasis.

Pamrevlumab plus chemotherapy failed to demonstrate a survival benefit in patients with locally advanced, unresectable pancreatic cancer.

Alexander I. Spira MD, PhD, FACP, FASCO, discusses data of RMC-9805 in previously treated, advanced KRAS G12D–mutated pancreatic ductal adenocarcinoma.

Surufatinib with TAS-102 produced promising survival outcomes and manageable toxicity as later-line therapy for a small cohort of patients with PDAC.

Nivolumab plus ipilimumab produced a statistically significant and clinically meaningful OS benefit vs SOC in systemic therapy–naive unresectable HCC.

Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.

TACE with camrelizumab and rivoceranib elicited a clinically meaningful PFS improvement among patients with unresectable HCC.

A subgroup analysis of the CABINET trial showed that cabozantinib extended PFS vs placebo in extrapancreatic NETs with a primary tumor arising in the GI tract.

Neoadjuvant sintilimab plus chemoradiotherapy improved pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.

Ajay Goel, PhD, AGAF, discusses upcoming clinical studies examining the prognostic biomarker CA19-9 plus an investigational exosome-based liquid biopsy for the detection of early-stage pancreatic cancer.

OS was not improved with pembrolizumab plus lenvatinib and chemotherapy vs chemotherapy alone in advanced HER2-negative gastroesophageal adenocarcinoma.

The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.

Researchers at Dana-Farber Cancer Institute have developed a breakthrough method to detect inflammation in the body using positron emission tomography (PET) imaging.

Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.

Tislelizumab plus irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin showcased encouraging efficacy and manageable safety in gastric/GEJ cancer.

Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.

SHR-1701 plus CAPOX chemotherapy elicited fewer chemo delays and dose reductions and improved AE data vs placebo plus CAPOX in HER2-negative gastric/GEJ cancer.

Evorpacept plus TRP produced superior ORR, DOR, and PFS outcomes vs TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer.

OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.

Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.

Yash Chhabra, PhD, Assistant Professor in the Cancer Signaling and Microenvironment Research Program, was recently honored with the American Association for Cancer Research’s NextGen Stars Award.

Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.

Tagitanlimab received marketing authorization from the Chinese NMPA for use with cisplatin and gemcitabine for patients with recurrent or metastatic NPC.

Maurie Markman, MD, delves into questions regarding precision medicine and genetic testing in cancer.

Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.

Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.

Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.

An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.

Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.

Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.